ENTA stock forecast
Our latest prediction for Enanta Pharmaceuticals, Inc.'s stock price was made on the July 6, 2018 when the stock price was at 125.30$.
In the short term (2weeks), ENTA's stock price should underperform the market by -0.58%. During that period the price should oscillate between -6.25% and +5.12%.
In the medium term (3months), ENTA's stock price should underperform the market by -2.62%. During that period the price should oscillate between -15.57% and +15.28%.Get email alerts
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
At the moment the company generates 238M USD in revenues.
On its last earning announcement, the company reported a profit of 4.13$ per share.
The book value per share is 18.62$
Three months stock forecastJuly 6, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|